Volume 6, Issue 4, August 2020, Page: 63-70
Metabolic Syndrome and Associated Factors Among HIV-infected Patients at Bafoussam Regional Hospital, Cameroon
Joel Martial Diesse, Department of Biochemistry, University of Dschang, Dschang, Cameroon
Cyril Wilfried Missinga, HIV Care Centre, Bafoussam Regional Hospital, Bafoussam, Cameroon
Aude Ngueguim Dougue, Department of Biochemistry, University of Yaounde 1, Yaounde, Cameroon
Emeline Zogning Makemjio, Department of Public Health, University of Dschang, Dschang, Cameroon
Stephen Tamekou Lacmata, Department of Biochemistry, University of Dschang, Dschang, Cameroon
Jean Paul Dzoyem, Department of Biochemistry, University of Dschang, Dschang, Cameroon
Jules-Roger Kuiate, Department of Biochemistry, University of Dschang, Dschang, Cameroon
Received: Aug. 12, 2020;       Accepted: Aug. 22, 2020;       Published: Sep. 7, 2020
DOI: 10.11648/j.ejcbs.20200604.13      View  86      Downloads  35
Abstract
The use of highly active antiretroviral therapy (HAART) transformed HIV infection to a chronic disease, and the complexity of the physiological disorders generated leads to the disruption of body fat distribution and insulin resistance. The resulting metabolic syndrome has rarely been investigated among people living with HIV/AIDS in Cameroon. The aim of the current work was to determine the prevalence of metabolic syndrome and associated factors among people living with HIV/AIDS under HAART at the Bafoussam Regional Hospital in Cameroon. A retrospective, cross-sectional study was conducted to collect demographic, clinical and therapeutic data from 371 people living with HIV/AIDS and who are under HAART at the Bafoussam Regional Hospital from November 2017 to February 2019. Abbott Real-time HIV-1 system, FACSCOUNT cytometer and FULLYSMART automates were used to determine HIV RNA level, CD4 cell count and biochemical parameters respectively. The metabolic syndrome was defined according to the International Diabetes Federation (IDF) and the National Cholesterol Education Program -Adult Treatment Panel III (NCEP-ATPIII) criteria. The overall prevalence of metabolic syndrome was 37.74% by IDF and 28.84% by ATPIII. Among patients with metabolic syndrome, HDL-hypocholesterolemia was the most prevalent feature (92.14%). We found that aging (OR, 1.05; p, 0.005), HIV RNA level (OR, 3.42; p, 0.001), family history of metabolic and coronary heart disease (OR, 2.24; P, 0.04), alcohol consumption (OR, 4; P, 0.004) and nutritional supplements (OR, 3.5; P<0.001) were the independent predictors of metabolic syndrome. Male sex (OR, 0.22; p,<0.001), use of traditional medicines (OR, 0.28; P<0.001), Cotrimoxazole prophylaxis (OR, 0.45; p, 0.007) and Lamivudine-Tenofovir-Efavirenz antiretroviral regimen (OR, 0.26; p<0.001) were protective factors. The prevalence of metabolic syndrome is on the increase among people living with HIV/AIDS in our study population. Both HIV related factors and traditional risk factors were associated with metabolic syndrome.
Keywords
Metabolic Syndrome, People Living with HIV/AIDS, HAART, Traditional Risk Factors
To cite this article
Joel Martial Diesse, Cyril Wilfried Missinga, Aude Ngueguim Dougue, Emeline Zogning Makemjio, Stephen Tamekou Lacmata, Jean Paul Dzoyem, Jules-Roger Kuiate, Metabolic Syndrome and Associated Factors Among HIV-infected Patients at Bafoussam Regional Hospital, Cameroon, European Journal of Clinical and Biomedical Sciences. Vol. 6, No. 4, 2020, pp. 63-70. doi: 10.11648/j.ejcbs.20200604.13
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645.
[2]
Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation. 2001; 104: 145-150.
[3]
Fezeu L, Balkau B, Kengne A-P, Sobngwi E, Mbanya JC. Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis. 2007; 193: 70-76.
[4]
Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, et al. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr. 1992; 55: 455-460.
[5]
Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993; 94: 515-519.
[6]
Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013; 5: 193ra91.
[7]
Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014; 10 (2): e1003829.
[8]
Irlam JH, Visser MME, Rollins NN, Siegfried N. (2010). Micronutrient supplementation in children and adults with HIV infection. Base de données des revues systématiques Cochrane; 12: CD003650.
[9]
Garcia OP. Micronutrients, immunology and inflammation effect of vitamin A deficiency on the immune response in obesity. Proceedings of the Nutrition Society. 5th International Immunonutrition Workshop 2012; 71: 290-297.
[10]
Hsue PY, Joan CL, Franklin A, Bolger AF, Martin JN, et al. Progression of atherosclerosis asassessed by carotid intima media thickness in patients with HIV infections. Circulation. 2004; 109: 1603-1608.
[11]
Ngatchou W, Lemogoum D, Ndobo P, Yagnigni E, Tiogou E, et al. Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. Vasc Health Risk Manag. 2013; 9: 509-516.
[12]
Sterne JAC, Hernan MA, Ledergerber B, Tilling K, Weber R, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005; 366 (9483): 378-84.
[13]
Wu P, Hung C, Liu W, Hsieh C, Sun H, et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother. 2012; 67 (4): 1001-1009.
[14]
Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, et al. Metabolic syndrome among HIV infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005; 28 (1): 132-137.
[15]
Elgalib A, Aboud M, Dimian C, Duncan A, Wierzbicki AS, Peters BS. The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. CMRO. 2011; 27 (1): 63-69.
[16]
Mbunkah HA, Mirikin HD, Kukwah AT, Nfor O, Nkuo-Akenji T. Prevalence of metabolic syndrome in human immunodeficiency virus-infected patients from the South-West region of Cameroun, using the adult treatement panel III criteria. Diabetol Metab Syndr. 2014; 6 (1): 92
[17]
Lepori M, Broccard FA, Schaller DM, Greub G. Acidose lactique chez les patients infectés par le VIH. Forum Médical Suisse. 2001; 38: 946-949.
[18]
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. JCH. 2008; 10 (5): 348-354.
[19]
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, et al. International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35: 1381-1395.
[20]
Haskell WL, Lee I-M, Pate RR, Powell KE, Blair SN, et al. Physical activity and public health: updated recommendation for adults from the American College of sports medicine and the American Heart Association. Med Sci Sports Exerc. 2007; 39: 1423-1434.
[21]
World Health Organization. Measuring obesity: classification and description of anthropometric data. Copenhagen: WHO 1989 (Nutr UD, EUR/ICP/NUT 125).
[22]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation; 106: 3143-3421.
[23]
Dimodi HT, Etame LS, Nguimkeng BS, Mbappe FE, Ndoe NE, et al. Prevalence of metabolic syndrome in HIV-Infected Cameroonian patients. World J AIDS. 2014; 4: 85-92.
[24]
Mapoure YN, Nkongni IN, Luma HN, Ngahane BHN, Barla E, et al. Incidence des accidents vasculaires cérébraux chez les patients VIH positifs sous traitement antirétroviral au long court. Pan Afr Med J. 2016; 24: 45.8013.
[25]
Mbanya D, Sama M, Tchounwou P. Current Status of HIV/AIDS in Cameroon: How Effective are Control Strategies? Int. J. Environ. Res. Public Health. 2008, 5 (5): 378-383.
[26]
Garcia-Calleja JM, Mvondo JL, Abbenyi SS, Zekeng L, Loius JP, et al. Profil de l’épidémie VIH/SIDA au Cameroun. Bull. Liais. Doc. OCEAC. 1992; 99: 31-33.
[27]
Ntusi NAB & Ntsekhe M. Human immunodeficiency virus-associated heart failure in sub-Saharan Africa: evolution in the epidemiology, pathophysiology, and clinical manifestations in the antiretroviral era. ESC Heart Failure. 2016; 3: 158-167.
[28]
Enyegue DM, Ngondi JL, Fomekong GI, Agbor G, Oben JE. Prediction and prevalence of metabolic syndrome in overweight and obese subject in cameroon. Int J Biomed Pharmaceut Sci. 2008; 2 (2): 117-121.
[29]
Ntentie FR, Ngondi JL, Azantsa KBG, Santy EV, Dimodi HT, et al. Urbanization and metabolic syndrome in Cameroon: alertness on less urbanised areas. Endocrinol Metab Syndr. 2014; 3: 137
[30]
Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Euro Heart J. 2013; 34 (46): 3538-3546.
[31]
Bernal E, Masia M, Padilla S, Gutierrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDs. 2008; 22 (7): 569-575.
[32]
Alencastro PR, Fuchs SC, Wolff FH, Ikeda ML, Brandao ABM, et al. Independent Predictors of Metabolic Syndrome in HIV-Infected Patients. AIDS Patient Care STDs. 2011; 24 (11). 627-634.
[33]
Boulougoura A & Sereti I. HIV infection and immune activation: the role of co-infections. Curr Opin HIV AIDS. 2016; 11 (2): 191-200.
[34]
Alassani A, Dovonou CA, Sossou E, Attinsounon CA, Gninkoun J, et al. Prévalence, facteurs associés et prédisposant au syndrome métabolique chez les personnes vivants avec le VIH sous traitement antirétroviral à Porto-Novo en 2014. Pan Afr Med J. 2015; 22 (1): 296.7923
[35]
Mandob DE, Fomekong GID, Ngondi JL. Prevalence of metabolic syndrome among Bamileke ethnic women Yaounde, Cameroon. Int J Pharm Bio Sci. 2013; 4 (4): (B) 255-262.
[36]
Kovatcheva-Datchary P & Arora T. Nutrition, the gut microbiome and the metabolic Syndrome. Best Pract Research Clin Gastroenterol. 2013; 27: 59-72.
Browse journals by subject